- Previous Close
21.67 - Open
21.78 - Bid --
- Ask --
- Day's Range
21.74 - 22.22 - 52 Week Range
18.41 - 31.03 - Volume
4,048,308 - Avg. Volume
3,453,591 - Market Cap (intraday)
21.662B - Beta (5Y Monthly) 1.03
- PE Ratio (TTM)
-- - EPS (TTM)
-0.89 - Earnings Date Mar 5, 2025
- Forward Dividend & Yield 0.11 (0.50%)
- Ex-Dividend Date Apr 28, 2025
- 1y Target Est
27.50
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.
www.bayer.com94,245
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BAYN.DE
View MorePerformance Overview: BAYN.DE
Trailing total returns as of 2/21/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BAYN.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BAYN.DE
View MoreValuation Measures
Market Cap
21.66B
Enterprise Value
53.95B
Trailing P/E
--
Forward P/E
1.66
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.46
Price/Book (mrq)
0.71
Enterprise Value/Revenue
1.15
Enterprise Value/EBITDA
5.76
Financial Highlights
Profitability and Income Statement
Profit Margin
-1.88%
Return on Assets (ttm)
5.11%
Return on Equity (ttm)
-2.73%
Revenue (ttm)
46.74B
Net Income Avi to Common (ttm)
-880M
Diluted EPS (ttm)
-0.89
Balance Sheet and Cash Flow
Total Cash (mrq)
6.34B
Total Debt/Equity (mrq)
134.10%
Levered Free Cash Flow (ttm)
5.47B